🇺🇸 FDA
Patent

US 11723873

Oral dosage form of ticagrelor and preparation method thereof

granted A61KA61K31/519A61K47/10

Quick answer

US patent 11723873 (Oral dosage form of ticagrelor and preparation method thereof) held by Elite Pharmaceutical Solution Inc. expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Elite Pharmaceutical Solution Inc.
Grant date
Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/519, A61K47/10, A61K9/0004, A61K9/0053